Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTC-STOP: Using circulating tumour cell counts to optimize docetaxel therapy in metastatic castration-resistant prostate cancer
2015-001361-27Phase 3Terminated
- Sponsor
- The Institute of Cancer Research
- Start
- Jul 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Overall survival. Started Jul 2020; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-001361-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001361-27.